Trifecta Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Trifecta Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674	Buy	+42	New	+$695	﹤0.01%	400

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Trifecta Capital Advisors's TAK Position: Q2 2026 in Review

Trifecta Capital Advisors opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 42 shares worth $674. The stake represents ﹤0.01% of the portfolio and ranks #400 among its holdings.

376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Trifecta Capital Advisors held 42 shares of Takeda Pharmaceutical worth $674 as of Q2 2026.
Takeda Pharmaceutical was a new Trifecta Capital Advisors position in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #400 holding.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.